Shares of 89bio, Inc. (NASDAQ:ETNB – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports.

(NASDAQ:ETNB – Get Free Report) had its price target boosted by stock analysts at UBS Group from $25.00 to $38.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a ...

StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Shares of 89bio, Inc. (NASDAQ:ETNB – Get Free Report) traded up 8.3% during mid-day trading on Thursday . The stock traded as high as $9.67 and last traded at $9.45. 1,627,349 shares traded hands ...